--- title: "Efocipegtrutide | PepTracker Pro" description: "Efocipegtrutide (Hanmi code HM15211) is an investigational, long-acting, once-weekly GLP-1/GIP/glucagon 'triple' receptor agonist being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) rather than obesity alone. It is built on Hanmi's LAPSCovery platform as a chemical conjugate of a chimeric tri-agonist peptide (TA15211) fused to a human IgG4 Fc fragment, which extends its half-life via FcRn-mediated recycling and enables weekly subcutaneous dosing. By adding glucagon-receptor activation to the GLP-1/GIP dual mechanism, efocipegtrutide is designed to combine appetite suppression and glycemic control with increased energy expenditure and direct hepatic anti-steatotic, anti-inflammatory, and anti-fibrotic effects. In a Phase 1b/2a study in obese subjects with non-alcoholic fatty liver disease, 12 weeks of treatment reduced liver fat by roughly 20% to 59% (dose-dependent, MRI-PDFF) versus about 6% on placebo. It has FDA Fast Track designation for MASH and orphan-drug designations from the FDA and EMA for primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and idiopathic pulmonary fibrosis (IPF). The 52-week adaptive Phase 2 HM-TRIA-201 study (NCT04505436) in biopsy-confirmed MASH with fibrosis is the pivotal read the field is watching." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Efocipegtrutide", "description": "Efocipegtrutide (Hanmi code HM15211) is an investigational, long-acting, once-weekly GLP-1/GIP/glucagon 'triple' receptor agonist being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) rather than obesity alone. It is built on Hanmi's LAPSCovery platform as a chemical conjugate of a chimeric tri-agonist peptide (TA15211) fused to a human IgG4 Fc fragment, which extends its half-life via FcRn-mediated recycling and enables weekly subcutaneous dosing. By adding glucagon-receptor activation to the GLP-1/GIP dual mechanism, efocipegtrutide is designed to combine appetite suppression and glycemic control with increased energy expenditure and direct hepatic anti-steatotic, anti-inflammatory, and anti-fibrotic effects. In a Phase 1b/2a study in obese subjects with non-alcoholic fatty liver disease, 12 weeks of treatment reduced liver fat by roughly 20% to 59% (dose-dependent, MRI-PDFF) versus about 6% on placebo. It has FDA Fast Track designation for MASH and orphan-drug designations from the FDA and EMA for primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and idiopathic pulmonary fibrosis (IPF). The 52-week adaptive Phase 2 HM-TRIA-201 study (NCT04505436) in biopsy-confirmed MASH with fibrosis is the pivotal read the field is watching.", "url": "https://peptrackerpro.com/peptides/efocipegtrutide", "lastReviewed": "2026-07-09", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Efocipegtrutide", "item": "https://peptrackerpro.com/peptides/efocipegtrutide" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People with MASH/NASH or fatty liver disease tracking next-generation therapies beyond GLP-1-only agents.?", "acceptedAnswer": { "@type": "Answer", "text": "Efocipegtrutide is a research peptide studied in preclinical models. Efocipegtrutide (Hanmi code HM15211) is an investigational, long-acting, once-weekly GLP-1/GIP/glucagon 'triple' receptor agonist being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) rather than obesity alone. It is built on Hanmi's LAPSCovery platform as a chemical conjugate of a chimeric tri-agonist peptide (TA15211) fused to a human IgG4 Fc fragment, which extends its half-life via FcRn-mediated recycling and enables weekly subcutaneous dosing. By adding glucagon-receptor activation to the GLP-1/GIP dual mechanism, efocipegtrutide is designed to combine appetite suppression and glycemic control with increased energy expenditure and direct hepatic anti-steatotic, anti-inflammatory, and anti-fibrotic effects. In a Phase 1b/2a study in obese subjects with non-alcoholic fatty liver disease, 12 weeks of treatment reduced liver fat by roughly 20% to 59% (dose-dependent, MRI-PDFF) versus about 6% on placebo. It has FDA Fast Track designation for MASH and orphan-drug designations from the FDA and EMA for primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and idiopathic pulmonary fibrosis (IPF). The 52-week adaptive Phase 2 HM-TRIA-201 study (NCT04505436) in biopsy-confirmed MASH with fibrosis is the pivotal read the field is watching." } }, { "@type": "Question", "name": "Clinicians and researchers comparing triple GLP-1/GIP/glucagon agonists (efocipegtrutide, retatrutide) and the specific role of glucagon in liver fibrosis.?", "acceptedAnswer": { "@type": "Answer", "text": "Efocipegtrutide is a research peptide studied in preclinical models. Efocipegtrutide (Hanmi code HM15211) is an investigational, long-acting, once-weekly GLP-1/GIP/glucagon 'triple' receptor agonist being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) rather than obesity alone. It is built on Hanmi's LAPSCovery platform as a chemical conjugate of a chimeric tri-agonist peptide (TA15211) fused to a human IgG4 Fc fragment, which extends its half-life via FcRn-mediated recycling and enables weekly subcutaneous dosing. By adding glucagon-receptor activation to the GLP-1/GIP dual mechanism, efocipegtrutide is designed to combine appetite suppression and glycemic control with increased energy expenditure and direct hepatic anti-steatotic, anti-inflammatory, and anti-fibrotic effects. In a Phase 1b/2a study in obese subjects with non-alcoholic fatty liver disease, 12 weeks of treatment reduced liver fat by roughly 20% to 59% (dose-dependent, MRI-PDFF) versus about 6% on placebo. It has FDA Fast Track designation for MASH and orphan-drug designations from the FDA and EMA for primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and idiopathic pulmonary fibrosis (IPF). The 52-week adaptive Phase 2 HM-TRIA-201 study (NCT04505436) in biopsy-confirmed MASH with fibrosis is the pivotal read the field is watching." } }, { "@type": "Question", "name": "Patients and advocates following orphan-designated options for cholestatic/fibrotic diseases such as PBC and PSC.?", "acceptedAnswer": { "@type": "Answer", "text": "Efocipegtrutide is a research peptide studied in preclinical models. Efocipegtrutide (Hanmi code HM15211) is an investigational, long-acting, once-weekly GLP-1/GIP/glucagon 'triple' receptor agonist being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) rather than obesity alone. It is built on Hanmi's LAPSCovery platform as a chemical conjugate of a chimeric tri-agonist peptide (TA15211) fused to a human IgG4 Fc fragment, which extends its half-life via FcRn-mediated recycling and enables weekly subcutaneous dosing. By adding glucagon-receptor activation to the GLP-1/GIP dual mechanism, efocipegtrutide is designed to combine appetite suppression and glycemic control with increased energy expenditure and direct hepatic anti-steatotic, anti-inflammatory, and anti-fibrotic effects. In a Phase 1b/2a study in obese subjects with non-alcoholic fatty liver disease, 12 weeks of treatment reduced liver fat by roughly 20% to 59% (dose-dependent, MRI-PDFF) versus about 6% on placebo. It has FDA Fast Track designation for MASH and orphan-drug designations from the FDA and EMA for primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and idiopathic pulmonary fibrosis (IPF). The 52-week adaptive Phase 2 HM-TRIA-201 study (NCT04505436) in biopsy-confirmed MASH with fibrosis is the pivotal read the field is watching." } }, { "@type": "Question", "name": "Investors and industry watchers following Hanmi's LAPSCovery long-acting peptide platform and the MASH drug race.?", "acceptedAnswer": { "@type": "Answer", "text": "Efocipegtrutide is a research peptide studied in preclinical models. Efocipegtrutide (Hanmi code HM15211) is an investigational, long-acting, once-weekly GLP-1/GIP/glucagon 'triple' receptor agonist being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) rather than obesity alone. It is built on Hanmi's LAPSCovery platform as a chemical conjugate of a chimeric tri-agonist peptide (TA15211) fused to a human IgG4 Fc fragment, which extends its half-life via FcRn-mediated recycling and enables weekly subcutaneous dosing. By adding glucagon-receptor activation to the GLP-1/GIP dual mechanism, efocipegtrutide is designed to combine appetite suppression and glycemic control with increased energy expenditure and direct hepatic anti-steatotic, anti-inflammatory, and anti-fibrotic effects. In a Phase 1b/2a study in obese subjects with non-alcoholic fatty liver disease, 12 weeks of treatment reduced liver fat by roughly 20% to 59% (dose-dependent, MRI-PDFF) versus about 6% on placebo. It has FDA Fast Track designation for MASH and orphan-drug designations from the FDA and EMA for primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and idiopathic pulmonary fibrosis (IPF). The 52-week adaptive Phase 2 HM-TRIA-201 study (NCT04505436) in biopsy-confirmed MASH with fibrosis is the pivotal read the field is watching." } } ] } ] --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Peptides](/peptides)/ Efocipegtrutide **Research-only content.** This page is for educational purposes and does not constitute medical advice. [Read full disclaimer →](/research-disclaimer) # Efocipegtrutide Medium Evidence Efocipegtrutide (Hanmi code HM15211) is an investigational, long-acting, once-weekly GLP-1/GIP/glucagon 'triple' receptor agonist being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) rather than obesity alone. It is built on Hanmi's LAPSCovery platform as a chemical conjugate of a chimeric tri-agonist peptide (TA15211) fused to a human IgG4 Fc fragment, which extends its half-life via FcRn-mediated recycling and enables weekly subcutaneous dosing. By adding glucagon-receptor activation to the GLP-1/GIP dual mechanism, efocipegtrutide is designed to combine appetite suppression and glycemic control with increased energy expenditure and direct hepatic anti-steatotic, anti-inflammatory, and anti-fibrotic effects. In a Phase 1b/2a study in obese subjects with non-alcoholic fatty liver disease, 12 weeks of treatment reduced liver fat by roughly 20% to 59% (dose-dependent, MRI-PDFF) versus about 6% on placebo. It has FDA Fast Track designation for MASH and orphan-drug designations from the FDA and EMA for primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and idiopathic pulmonary fibrosis (IPF). The 52-week adaptive Phase 2 HM-TRIA-201 study (NCT04505436) in biopsy-confirmed MASH with fibrosis is the pivotal read the field is watching. Aliases Efocipegtrutide +5 more Evidence Medium Evidence Last Updated 2026-07-09 Reading Time 5 min ## Table of Contents 1. [What It Is](#what-it-is) 2. [Regulatory Status](#regulatory-status) 3. [Why Researchers Study It](#why-researchers-study) 4. [Proposed Mechanisms](#proposed-mechanisms) 5. [Evidence Snapshot](#evidence-snapshot) 6. [Commonly Discussed Benefits](#benefits) 7. [Safety & Cautions](#safety) 8. [Comparisons](#comparisons) 9. [Calculator Tools](#calculator) 10. [Citations](#citations) ## What It Is Efocipegtrutide (HM15211) is an investigational, once-weekly, subcutaneously injected triple receptor agonist that simultaneously activates the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It is developed by South Korea's Hanmi Pharmaceutical, which brands the molecule a 'LAPSTriple Agonist.' Structurally it is a chemical conjugate of a chimeric peptide (TA15211) engineered to hit all three receptors, linked to a human immunoglobulin G4 (IgG4) Fc fragment through Hanmi's proprietary LAPSCovery (Long-Acting Protein/Peptide Discovery) technology. The Fc partner acts as a molecular carrier that engages the neonatal Fc receptor (FcRn) recycling pathway, protecting the peptide from clearance and dramatically extending its in-vivo half-life so it can be dosed once weekly. Unlike the obesity-first triple agonist retatrutide, efocipegtrutide is being positioned principally as a liver-disease drug for MASH (metabolic dysfunction-associated steatohepatitis, previously NASH) and cholestatic/fibrotic conditions. The mechanistic logic of adding glucagon to the incretin backbone is threefold: GLP-1 activation suppresses appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion; GIP activation adds insulinotropic effect and is thought to improve tolerability; and glucagon activation raises energy expenditure and acts directly on hepatocytes to promote lipolysis and reduce hepatic fat, while also contributing anti-inflammatory and anti-fibrotic effects in the liver. Preclinical work from Hanmi (presented at EASL and AASLD) indicates that the glucagon component is essential to the direct anti-inflammatory and anti-fibrotic activity seen in chemically induced (TAA/CCl4) mouse models of liver injury, distinguishing a triple agonist from GLP-1-only or GLP-1/GIP agents whose liver benefit is largely secondary to weight loss. Clinically, a Phase 1b/2a randomized, double-blind, placebo-controlled study in obese subjects with non-alcoholic fatty liver disease showed dose-dependent reductions in liver fat content (MRI-PDFF) of approximately 19.6% (lowest dose) to 59.3% (highest dose) at week 12, versus roughly 5.7% with placebo, alongside body-weight reductions. Efocipegtrutide holds U.S. FDA Fast Track designation for MASH (granted 2020) and orphan-drug designations from both the FDA and EMA for PBC, PSC, and IPF. The current pivotal program is HM-TRIA-201 (NCT04505436), a Phase 2, adaptive, randomized, double-blind, placebo-controlled, multicenter, 52-week study in patients with biopsy-confirmed MASH and fibrosis conducted in the U.S. and Korea; its Independent Data Monitoring Committee has recommended the trial continue without modification. Efocipegtrutide is an investigational, manufacturer-developed biologic studied only in regulated clinical trials - it is not an approved medicine and not a self-sourced 'research peptide.' Also known as: Efocipegtrutide, HM15211, LAPSTriple Agonist, GLP-1/GIP/glucagon triple receptor agonist (Hanmi), Hanmi HM15211, long-acting triple incretin agonist ## Regulatory Status Investigational Investigational (not approved by any regulator). FDA Fast Track for MASH; FDA and EMA orphan-drug designations for PBC, PSC, and IPF. No marketing application yet. ## Why Researchers Study It Efocipegtrutide is a leading test of whether adding glucagon-receptor agonism to the GLP-1/GIP incretin backbone can deliver liver-directed benefit in MASH that goes beyond what weight loss alone achieves - reducing steatosis, inflammation, and fibrosis through direct hepatic and energy-expenditure mechanisms. Its MASH-first (rather than obesity-first) positioning, its Fc-fusion long-acting design, and its orphan-designated potential in cholestatic/fibrotic diseases (PBC, PSC, IPF) make it a distinct data point in the crowded incretin field. ## Proposed Mechanisms - GLP-1 receptor agonism: enhances glucose-dependent insulin secretion, suppresses glucagon after meals, slows gastric emptying, and reduces appetite and food intake via central and peripheral pathways. - GIP receptor agonism: provides additional insulinotropic effect and is thought to improve the metabolic and tolerability profile of the combined agonist. - Glucagon receptor agonism: increases energy expenditure and acts directly on hepatocytes to stimulate lipolysis and reduce hepatic fat, contributing anti-steatotic, anti-inflammatory, and anti-fibrotic effects in preclinical liver-injury models. - Balanced tri-agonism: the chimeric TA15211 peptide is tuned so glucagon-driven catabolic/hepatic effects complement GLP-1/GIP glycemic and appetite effects without provoking hyperglycemia. - FcRn-mediated half-life extension (LAPSCovery): fusion to an IgG4 Fc fragment engages neonatal Fc receptor recycling, slowing clearance and enabling once-weekly subcutaneous dosing. ## Evidence Snapshot Medium Evidence Low Medium High Study Type Model Outcome Link RCT (human, Phase 1b/2a) Obese subjects with non-alcoholic fatty liver disease; once-weekly subcutaneous HM15211 (dose range up to 0.06 mg/kg) vs placebo over 12 weeks Dose-dependent reduction in liver fat (MRI-PDFF) of ~19.6% (lowest dose) to ~59.3% (highest dose) at week 12 vs ~5.7% with placebo; accompanied by body-weight reduction; generally tolerable [Source](https://www.hanmipharm.com/science/pipeline/focused/efocipegtrutide.hm) RCT (human, Phase 2 - HM-TRIA-201, ongoing) Patients with biopsy-confirmed MASH and fibrosis; adaptive, randomized, double-blind, placebo-controlled, multicenter, 52-week study (US and Korea); NCT04505436 Pivotal Phase 2 designed to assess histologic MASH resolution and fibrosis improvement; Independent Data Monitoring Committee recommended continuing the trial without modification [Source](https://clinicaltrials.gov/study/NCT04505436) Preclinical / mechanistic TAA- and CCl4-induced mouse models of liver inflammation and fibrosis; comparison of triple agonism with removal of glucagon activity HM15211 produced anti-inflammatory and anti-fibrotic effects; glucagon-receptor engagement was essential for the direct anti-inflammation/anti-fibrosis benefit, distinguishing it from GLP-1/GIP-only agents (EASL/AASLD posters) [Source](https://www.hanmi.co.kr/science-pdf/HM15211/2023_EASL_poster_efocipegtrutide_CCl4.pdf) Regulatory milestone FDA and EMA designation decisions for HM15211 FDA Fast Track designation for MASH (2020); FDA and EMA orphan-drug designations for primary biliary cholangitis, primary sclerosing cholangitis, and idiopathic pulmonary fibrosis [Source](https://www.koreabiomed.com/news/articleView.html?idxno=23989) ## Commonly Discussed Benefits [Liver Health](/benefits/liver-health)[Weight Management](/benefits/weight-management)[Glycemic Control](/benefits/glycemic-control)[Metabolism](/benefits/metabolism) Researching Efocipegtrutide ? Track it, set reminders, and keep notes in the free app. [Track in App](https://app.peptrackerpro.com/?add=efocipegtrutide) ## Safety & Cautions - Investigational and not approved: efocipegtrutide is in Phase 2 development and is not available by prescription; its efficacy and safety in MASH remain to be confirmed in ongoing and future trials. - No self-sourcing: HM15211 is a proprietary Hanmi biologic (a peptide-Fc conjugate) studied only in controlled trials. Material sold online as 'efocipegtrutide' or 'HM15211' is not the clinical drug and cannot be assumed authentic, pure, or safe. - Gastrointestinal effects: as a GLP-1/GIP/glucagon agonist it is expected to cause nausea, vomiting, and diarrhea, usually mild-to-moderate and dose-dependent during titration. - Glucagon-related effects: glucagon-receptor activation can raise glucose and heart rate and increase energy expenditure; balancing these against the incretin components is a key safety question for triple agonists and requires monitoring. - Liver-endpoint uncertainty: promising liver-fat (MRI-PDFF) reductions are a surrogate; histologic MASH resolution and fibrosis improvement in the 52-week Phase 2 (and any Phase 3) are what establish clinical benefit. - Early-stage evidence: much supporting data are preclinical or Phase 1b/2a and, in some cases, conference posters rather than full peer-reviewed publications; conclusions should be treated as preliminary. ## Comparisons See how Efocipegtrutide compares to related peptides: [Efocipegtrutide vs Tirzepatide](/compare/efocipegtrutide-vs-tirzepatide) [Efocipegtrutide vs Retatrutide](/compare/efocipegtrutide-vs-retatrutide) [Efocipegtrutide vs Survodutide](/compare/efocipegtrutide-vs-survodutide) [Efocipegtrutide vs Mazdutide](/compare/efocipegtrutide-vs-mazdutide) [Efocipegtrutide vs Pemvidutide](/compare/efocipegtrutide-vs-pemvidutide) [Efocipegtrutide vs Pegozafermin](/compare/efocipegtrutide-vs-pegozafermin) [Efocipegtrutide vs Efruxifermin](/compare/efocipegtrutide-vs-efruxifermin) [Efocipegtrutide vs Efinopegdutide](/compare/efocipegtrutide-vs-efinopegdutide) ## Calculator Tools Use our research tools to explore dosing and reconstitution data: [Reconstitution Calculator](/calculators) ## Citations 1. \[1\] Efocipegtrutide (HM15211) pipeline overview - Hanmi Pharmaceutical [PubMed](https://www.hanmipharm.com/science/pipeline/focused/efocipegtrutide.hm) 2. \[2\] Study to Evaluate Efficacy, Safety and Tolerability of HM15211 (Efocipegtrutide) - HM-TRIA-201 (ClinicalTrials.gov NCT04505436) [PubMed](https://clinicaltrials.gov/study/NCT04505436) 3. \[3\] A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in biopsy-confirmed NASH - design and rationale (HM-TRIA-201) [PubMed](https://www.sciencedirect.com/science/article/abs/pii/S155171442300099X) 4. \[4\] Hanmi Pharm's efocipegtrutide Phase 2 MASH trial gets green light from IDMC (Korea Biomedical Review) [PubMed](https://www.koreabiomed.com/news/articleView.html?idxno=23989) 5. \[5\] Hanmi showcases efocipegtrutide's potential for liver fibrosis at AASLD (Korea Biomedical Review) [PubMed](https://www.koreabiomed.com/news/articleView.html?idxno=25908) 6. \[6\] HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with NAFLD (Phase 1b/2a) [PubMed](https://www.researchgate.net/publication/345087990) 7. \[7\] Next generation dual and triple GLP-1/GIP/glucagon agonists: a literature review (Nutr Metab Cardiovasc Dis) [PubMed](https://www.nmcd-journal.com/article/S0939-4753\(25\)00367-9/abstract) ### Keep researching in the app - Log Efocipegtrutide to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack [Open PepTracker Pro Free](https://app.peptrackerpro.com/?add=efocipegtrutide) [Browse more peptides](/peptides) ## Related Peptides ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+1 more [View Details](/peptides/tirzepatide) [\+ Compare](/compare?select=tirzepatide)[](https://app.peptrackerpro.com/?add=tirzepatide) ### Retatrutide High Evidence An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/retatrutide) [\+ Compare](/compare?select=retatrutide)[](https://app.peptrackerpro.com/?add=retatrutide) ### Survodutide Medium Evidence A dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/survodutide) [\+ Compare](/compare?select=survodutide)[](https://app.peptrackerpro.com/?add=survodutide) ### Mazdutide High Evidence The first dual GCG/GLP-1 receptor agonist approved in China for obesity and T2D, with Phase 3 showing up to 20.1% weight loss at the 9 mg dose and superiority over semaglutide. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism) [View Details](/peptides/mazdutide) [\+ Compare](/compare?select=mazdutide)[](https://app.peptrackerpro.com/?add=mazdutide) ### Pemvidutide Medium Evidence A GLP-1/glucagon dual receptor agonist with FDA Breakthrough Therapy Designation for MASH, showing strong weight loss and liver benefits in Phase 2 trials. [Weight Management](/benefits/weight-management)[Fat Loss](/benefits/fat-loss)[Liver Health](/benefits/liver-health)[Metabolism](/benefits/metabolism) [View Details](/peptides/pemvidutide) [\+ Compare](/compare?select=pemvidutide)[](https://app.peptrackerpro.com/?add=pemvidutide) ### Pegozafermin Low Evidence Pegozafermin (development code BIO89-100) is an investigational, long-acting analog of fibroblast growth factor 21 (FGF21) being developed for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and for severe hypertriglyceridemia (SHTG). Originally developed by 89bio and acquired by Roche in a deal announced in September 2025 (about $2.4 billion upfront and up to roughly $3.5 billion including a contingent value right), it uses site-specific glycoPEGylation to extend the very short half-life of native FGF21 to roughly 55-100 hours, enabling once-weekly or once-every-two-weeks subcutaneous dosing. FGF21 is a metabolic hormone that acts on liver, fat, and other tissues to improve insulin sensitivity, lower triglycerides, and exert direct anti-fibrotic and anti-inflammatory effects. In the Phase 2b ENLIVEN trial in biopsy-confirmed F2-F3 MASH, the 44 mg every-two-weeks dose produced at least a one-stage fibrosis improvement without worsening of MASH in about 27% of patients versus 7% on placebo, and MASH resolution without worsening of fibrosis in about 26% versus 2% on placebo, with benefits sustained through week 48. Pegozafermin holds FDA Breakthrough Therapy designation and EMA PRIME status for MASH and has advanced into the Phase 3 ENLIGHTEN program (ENLIGHTEN-Fibrosis in non-cirrhotic F2-F3 MASH and ENLIGHTEN-Cirrhosis in compensated F4 cirrhosis), plus the Phase 3 ENTRUST trial in SHTG. [metabolic dysfunction-associated steatohepatitis (MASH/NASH) - fibrosis improvement, MASH resolution, and reduced liver fat (investigational)]()[severe hypertriglyceridemia (SHTG) - large reductions in blood triglycerides (investigational; Phase 3 ENTRUST)]()[improved insulin sensitivity and glycemic markers]()[improvements in non-invasive markers of liver injury and fibrosis (liver fat by MRI-PDFF, liver enzymes, fibrosis biomarkers)]()+1 more [View Details](/peptides/pegozafermin) [\+ Compare](/compare?select=pegozafermin)[](https://app.peptrackerpro.com/?add=pegozafermin) ### Efruxifermin Low Evidence Efruxifermin (development codes EFX, AKR-001; originally AMG 876) is an investigational, once-weekly, subcutaneously injected analog of the metabolic hormone fibroblast growth factor 21 (FGF21) being developed by Akero Therapeutics for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), including both pre-cirrhotic fibrosis and compensated (F4) cirrhosis. It is a bivalent Fc-FGF21 fusion protein - two engineered FGF21 sequences fused to a human immunoglobulin (IgG1) Fc domain - a design distinct from the glycoPEGylation used by its main FGF21-class rival, pegozafermin. The Fc fusion extends the very short half-life of native FGF21 to support once-weekly dosing while preserving agonism at FGF receptors (FGFR1c/2c/3c) together with the co-receptor beta-Klotho. In the 96-week Phase 2b HARMONY trial in biopsy-confirmed F2-F3 MASH, at least a one-stage improvement in fibrosis without worsening of MASH was reached by about 75% of patients on 50 mg and 46% on 28 mg versus 24% on placebo (published in The Lancet, August 2025). In the Phase 2b SYMMETRY trial in compensated MASH cirrhosis, about 39% of 50 mg patients with paired week-96 biopsies achieved reversal of cirrhosis without worsening of MASH versus 15% on placebo (published in the New England Journal of Medicine). Efruxifermin holds FDA Breakthrough Therapy designation and has advanced into the Phase 3 SYNCHRONY program (SYNCHRONY Histology in F2-F3 MASH, SYNCHRONY Outcomes in F4 compensated cirrhosis, and SYNCHRONY Real-World in non-invasively diagnosed MASH/MASLD, whose double-blind portion completed enrollment with safety results expected in 2026). [metabolic dysfunction-associated steatohepatitis (MASH/NASH) - fibrosis improvement and MASH resolution in pre-cirrhotic F2-F3 disease (investigational)]()[reversal of compensated (F4) cirrhosis due to MASH without worsening of MASH (investigational; Phase 2b SYMMETRY, Phase 3 SYNCHRONY Outcomes)]()[reductions in liver fat (MRI-PDFF), liver enzymes, and non-invasive fibrosis biomarkers]()[improved insulin sensitivity, glycemic markers, and blood lipids (lower triglycerides, improved cholesterol profile)]()+1 more [View Details](/peptides/efruxifermin) [\+ Compare](/compare?select=efruxifermin)[](https://app.peptrackerpro.com/?add=efruxifermin) ### Efinopegdutide Medium Evidence Efinopegdutide (MK-6024, formerly HM12525A and JNJ-64565111) is an investigational once-weekly subcutaneous dual agonist of the GLP-1 and glucagon receptors being developed by Merck for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and steatotic liver disease. It is a synthetic oxyntomodulin-based peptide - a modified GLP-1/glucagon dual-agonist sequence conjugated to a human IgG4 Fc fragment through a 10 kDa polyethylene glycol linker using Hanmi Pharmaceutical's LAPSCovery half-life-extension platform, which stretches dosing to once weekly. The design pairs the GLP-1 arm (appetite suppression, glycemic control, weight loss) with a glucagon arm that raises energy expenditure and acts directly on the liver to burn hepatic fat - the feature that sets it apart from pure GLP-1 drugs. In the head-to-head Phase 2a trial in NAFLD (Journal of Hepatology, 2023), efinopegdutide 10 mg cut liver fat content by 72.7% at 24 weeks versus 42.3% for semaglutide 1 mg, with two-thirds of efinopegdutide recipients falling below the 5% liver-fat threshold that defines a normal liver. Merck holds FDA Fast Track designation for the MASH program and is running Phase 2b studies plus a dedicated trial in compensated cirrhosis due to steatohepatitis; the earlier type 2 diabetes and obesity indications were discontinued in favor of the liver focus. [metabolic-health](/benefits/metabolic-health)[Liver Health](/benefits/liver-health)[Weight Management](/benefits/weight-management)[disease-modification](/benefits/disease-modification)+1 more [View Details](/peptides/efinopegdutide) [\+ Compare](/compare?select=efinopegdutide)[](https://app.peptrackerpro.com/?add=efinopegdutide) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.